Full-Time

Lead Engineer

IAM Platform Engineering

Updated on 9/12/2026

Deadline 9/25/26
Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Carrollton, TX, USA + 1 more

More locations: Conshohocken, PA, USA

In Person

Bachelor's, Master's

Category
Cybersecurity (1)
Required Skills
LLM
PowerShell
Python
JavaScript
LDAP
Machine Learning
Infrastructure as Code (IaC)
SAML
Terraform
REST APIs
OAuth

Get referred to Cencora

See people who can refer or advise you

Requirements
  • A bachelor's degree in Computer Science, Information Technology, Cybersecurity, Software Engineering, Data Science, or a related field, or equivalent experience.
  • At least 6 years of experience in IAM, platform engineering, cybersecurity engineering, software development, cloud engineering, or related disciplines.
  • Demonstrated experience designing and deploying IAM automation solutions using APIs, scripting, workflow orchestration, or automation platforms.
  • Hands-on experience with identity technologies such as SailPoint, Saviynt, Okta, Entra ID, Ping Identity, CyberArk, ForgeRock, or BeyondTrust, or equivalent platforms.
  • Experience developing automation using PowerShell, Python, JavaScript, Terraform, REST APIs, or similar technologies.
  • Strong understanding of identity protocols including OAuth 2.0, OpenID Connect, SAML, SCIM, LDAP, and JWT.
  • Experience designing solutions that support Identity Governance, Access Management, Privileged Access Management, and Zero Trust initiatives.
  • Knowledge of artificial intelligence, machine learning, large language models, intelligent automation, or analytics platforms as applied to identity and cybersecurity use cases.
Responsibilities
  • Lead the strategic design, implementation, and continuous evolution of enterprise IAM platforms supporting workforce, privileged, third-party, and customer identities.
  • Architect and deliver automation solutions that streamline identity lifecycle management, access provisioning, deprovisioning, certification campaigns, privileged access controls, and compliance reporting.
  • Design and develop API-driven integrations, identity orchestration workflows, and Infrastructure-as-Code capabilities to reduce manual effort and improve operational scalability.
  • Evaluate and implement artificial intelligence and machine learning capabilities within IAM processes to support intelligent access recommendations, anomaly detection, automated role mining, access analytics, and identity risk scoring.
  • Partner with security operations, enterprise architecture, cloud engineering, and application teams to integrate automated identity controls into enterprise technology ecosystems.
  • Lead the development of self-service identity solutions that improve user experience while maintaining governance and security controls.
  • Design automation frameworks leveraging scripting, workflow engines, low-code/no-code platforms, and AI-powered tools to accelerate onboarding, access requests, and operational support processes.
  • Analyze identity telemetry, authentication patterns, privileged access activity, and behavioral analytics to identify security risks and opportunities for automation.
  • Advise senior technology leadership on emerging trends in Identity Threat Detection and Response, AI for cybersecurity, identity analytics, and intelligent identity governance.
  • Lead architecture decisions involving Identity Governance and Administration, Privileged Access Management, Single Sign-On, Multi-Factor Authentication, Passwordless Authentication, and Zero Trust security architectures.
  • Develop enterprise standards, architecture patterns, and reusable automation frameworks that improve consistency and accelerate platform delivery.
  • Design resilient identity solutions that support cloud-first technologies, digital transformation initiatives, and evolving regulatory requirements.
  • Mentor engineers and architects on automation best practices, AI adoption, secure development principles, and modern identity architecture patterns.
  • Evaluate emerging IAM, automation, and AI technologies to influence strategic investments and long-term platform modernization initiatives.
Desired Qualifications
  • A master's degree in Computer Science, Cybersecurity, Artificial Intelligence, Data Science, Information Technology, or a related field.
  • Experience implementing AI-driven identity governance, access analytics, role mining, threat detection, or access certification solutions.
  • Experience integrating generative AI, copilots, chatbots, or intelligent assistants into IAM operational processes.
  • Experience with Identity Threat Detection and Response platforms and User and Entity Behavior Analytics technologies.
  • Industry certifications such as CISSP, CISM, CCSP, Microsoft Cybersecurity Architect, SailPoint, Saviynt, CyberArk, Okta, AWS, Azure, or Google Cloud certifications.
  • Experience leading enterprise-scale IAM modernization or automation transformation programs.

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Fiscal 2026 Q3 revenue reached $84.8 billion, and EPS guidance rose to $17.75-$17.95.
  • Cencora completed OneOncology in February 2026, strengthening specialty-pharmacy and oncology economics.
  • A $7 billion revolver and $1 billion buyback show lenders and management backing execution.

What critics are saying

  • Opioid litigation still carries a $4.2 billion accrued liability through 2039.
  • Maryland courts vacated Baltimore's $152 million verdict, but appeals can revive distributor exposure.
  • ASP rule changes and 340B guidance threaten community-oncology margins by 2028, hitting OneOncology.

What makes Cencora unique

  • Cencora pairs drug distribution with OneOncology, deepening specialty-care workflow integration.
  • Its global network spans U.S. Healthcare Solutions and International Healthcare Solutions across 51,000 employees.
  • Nucleus inventory tools and cell-gene therapy enablement embed Cencora inside provider operations.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Company News

Associated Press
Sep 2nd, 2026
Cencora launches cell and gene therapy service to help health systems scale advanced treatment programmes

Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.

Yahoo Finance
Aug 14th, 2026
Cencora beats Q2 profit estimates as specialty pharma platform drives growth

Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.

Yahoo Finance
Aug 12th, 2026
Cencora raises FY2026 guidance after Q3 EPS jumps 12%, buys back $1B in shares

Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.

MarketScreener
Aug 5th, 2026
Cencora boosts credit facility to $7B, extends maturity to 2031

Cencora and its subsidiary Innomar Strategies have amended their credit agreement, increasing their multi-currency revolving credit facility from $5.5 billion to $7.0 billion. The facility's maturity date has been extended to July 2031. Interest rates on borrowings range from 69.5 to 110 basis points over various term rates, depending on Cencora's public debt ratings. The agreement includes covenants such as a maximum financial leverage ratio. Separately, on 31 July 2026, Cencora amended its receivables securitisation facility, reducing it from $1.5 billion to $1.0 billion whilst increasing the accordion feature from $500 million to $1.0 billion. This gives the company the option to expand commitments by up to $1.0 billion, subject to bank approval.

Yahoo Finance
Aug 1st, 2026
Cencora Q3 earnings preview: analysts expect $4.37 EPS on $84.89B revenue

Wall Street analysts expect Cencora to report quarterly earnings of $4.37 per share, marking a 9.3% year-over-year increase. Revenues are projected to reach $84.89 billion, up 5.2% from the same quarter last year. Over the past 30 days, the consensus earnings per share estimate has been revised upward by 1.3%. Analysts forecast revenue from Total US Healthcare Solutions at $75 billion, representing 2.9% year-over-year growth. International Healthcare Solutions revenue is expected to remain flat at $7.79 billion. Operating income projections show US Healthcare Solutions at $940.87 million and International Healthcare Solutions at $158.45 million. Cencora shares have risen 5.3% over the past month and hold a Zacks Rank of 2, indicating expected outperformance versus the broader market.